1. Lilly M, Godwin M. Treating prediabetes with metformin. Can Fam Physician 2009;55:363-9.
2. Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol Clin North Am. 2018;47(1):33–50. Doi: 10.1016/j.ecl.2017.10.001
3. Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. Doi: https://doi.org/10.1136/bmj.m2297
4. Schlesinger S, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022;65:275–285. https://doi.org/10.1007/s00125-021-05592-3
5. Galaviz, et al. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis. Am J Prev Med. 2022;62(4):614–625. doi:10.1016/j.amepre.2021.10.020
6. Hostalek U, Campbell I. Metformin for diabetes prevention: update of the evidence base. Current Medical Research and Opinion. 2021. DOI:10.1080/03007995.2021.1955667.
7. Chiou TT, Ge Y, Romley JA. Trends in Metformin Use Among Patients With Prediabetes: 2008–2020. Diabetes Care. 2023;46:e1–e2. https://doi.org/10.2337/dc22-0985
8. Davidson MB. Should Prediabetes be Treated Pharmacologically?. Diabetes Ther. 2023;14:1585–1593. https://doi.org/10.1007/s13300-023-01449-7.
9. Zheng M, Soumya, et al. Do patients with prediabetes managed with metformin achieve better glycaemic control? A national study using primary care medical records. Diabetic Medicine. 2023;40:e15170. https://doi.org/10.1111/dme.15170
10. Mousavi et al. Comparing the effectiveness of metformin with lifestyle modification for the primary prevention of type II diabetes: a systematic review and meta‑analysis. BMC Endocrine Disorders. 2023;23:198. https://doi.org/10.1186/s12902-023-01445-9
11. Davidson MB. Metformin Should Not Be Used to Treat Prediabetes. Diabetes Care. 2020;43:1983–1987. https://doi.org/10.2337/dc19-2221
12. Warrilow A, Somerset S, et al. Metformin Use in Prediabetes: is earlier intervention better? Acta Diabetol. 2020;57(11):1359-1366. Doi:10.1007/s00592-020-01559-9.
13. Walker EA, Gonzalez JS, et al. Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Res Care. 2020;8(1):e001537. doi: 10.1136/bmjdrc-2020-001537.
14. Gottwald-Hostalek U, Gwilt M. Vascular complications in prediabetes and type 2 diabetes: a continuous process arising from a common pathology. Curr Med Res Opin. 2022;38(11):1841-1851.
15. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243–2251. Doi: 10.1016/S0140-6736(12)60525-X.
16. Echouffo-Tcheugui JB, Niiranen TJ, McCabe EL, et al. Lifetime prevalence and prognosis of prediabetes without progression to diabetes. Diabetes Care. 2018;41:e117–e118 doi: 10.2337/dc18-0524.
17. Shang Y, Marseglia A, Fratiglioni L, et al. Natural history of prediabetes in older adults from a population-based longitudinal study. J Intern Med. 2019;286:326–340 doi:10.1111/joim.12920
18. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–1105. doi: https://doi.org/10.1016/S0140-6736(06)694208
19. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 2011;54:487–495. doi: 10.1007/s00125-010-1985-4.
20. Hwang Y-C, Cho I-J, Jeong I-K, Ahn KJ, Chung HY. Factors associated with regression from prediabetes to normal glucose tolerance in a Korean general population: a community-based 10-year prospective cohort study. Diabet Med. 2018;35:1544–1551. doi:10.1111/dme.13789.
21. Vistisen D, et al. Reversion from prediabetes to normoglycaemia and risk of cardiovascular disease and mortality: the Whitehall II cohort study. Diabetologia. 2019; 62:1385–1390. doi: 10.1007/s00125-019-4895-0.
22. Richter B, Hemmingsen B, Metzendorf MI, Takwoingi Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database Syst Rev. 2018;10:CD012661. doi: 10.1002/14651858.CD012661.pub2
23. American Diabetes Association. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Supplement_1):S34-S39. https://doi.org/10.2337/dc21-S003
24. Perkumpulan Endokrinologi Indonesia. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia. 2021. https://pbperkeni.or.id/2023